These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 5106102)

  • 1. Life history and symptoms in schizophrenia. Severity at hospitalization and response to phenothiazines.
    Schooler NR; Boothe H; Goldberg SC
    Arch Gen Psychiatry; 1971 Aug; 25(2):138-47. PubMed ID: 5106102
    [No Abstract]   [Full Text] [Related]  

  • 2. Prediction of improvement in schizophrenia under four phenothiazines.
    Goldberg SC; Mattsson N; Cole JO; Klerman GL
    Arch Gen Psychiatry; 1967 Jan; 16(1):107-17. PubMed ID: 6066689
    [No Abstract]   [Full Text] [Related]  

  • 3. Differences in clinical effects of three phenothiazines in "acute" schizophrenia.
    Dis Nerv Syst; 1967 Jun; 28(6):369-83. PubMed ID: 5342391
    [No Abstract]   [Full Text] [Related]  

  • 4. Specific indications for different classes of phenothiazines.
    Hollister LE; Overall JE; Kimbell I; Pokorny A
    Arch Gen Psychiatry; 1974 Jan; 30(1):94-9. PubMed ID: 4148660
    [No Abstract]   [Full Text] [Related]  

  • 5. Relative efficacy of butaperazine and chlorpromazine in acute schizophrenia.
    Gershon S; Hekimian LJ; Burdock EI; Park S; Floyd A
    Curr Ther Res Clin Exp; 1970 Dec; 12(12):810-8. PubMed ID: 4396420
    [No Abstract]   [Full Text] [Related]  

  • 6. Schizophrenic subtypes defined by response to drugs and placebo.
    Goldberg SC; Mattsson NB
    Dis Nerv Syst; 1968 May; 29(5):Suppl:153-8. PubMed ID: 4876985
    [No Abstract]   [Full Text] [Related]  

  • 7. Dyskinesia and neuroleptics.
    Crane GE
    Arch Gen Psychiatry; 1968 Dec; 19(6):700-3. PubMed ID: 5697636
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of butaperazine in chronic schizophrenia.
    Clark ML; Ray TS; Huber WK; Willis D; Ramsey HR
    Clin Pharmacol Ther; 1968; 9(6):757-64. PubMed ID: 4387043
    [No Abstract]   [Full Text] [Related]  

  • 9. Paranoid and withdrawal symptoms in schizophrenia: differential symptom reduction over time.
    Goldberg SC; Schooler NR; Mattsson N
    J Nerv Ment Dis; 1967 Aug; 145(2):158-62. PubMed ID: 4861752
    [No Abstract]   [Full Text] [Related]  

  • 10. Performance tests in a study of phenothiazines in schizophrenia: caveats and conclusions.
    Schooler NR; Goldberg SC
    Psychopharmacologia; 1972; 24(1):81-98. PubMed ID: 5062969
    [No Abstract]   [Full Text] [Related]  

  • 11. Temporal changes in handwriting size, level of premorbid social functioning and intellectural level during treatment in acute schizophrenics.
    Downing RW; Ebert JN; Boruchow JK; Valentine JH
    J Nerv Ment Dis; 1966 Jun; 142(6):526-33. PubMed ID: 5920205
    [No Abstract]   [Full Text] [Related]  

  • 12. [ECG picture in the course of treatment of schizophrenia with phenothiazine derivatives].
    Welbel L; Zalewski K
    Psychiatr Pol; 1971; 5(1):49-54. PubMed ID: 5551991
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparative study of butaperazine and prochlorperazine for schizophrenia in acute phase].
    Albert JM; Rajotte P; Rajotte E; Tétreault L
    Union Med Can; 1970 Jul; 99(7):1282-5. PubMed ID: 4396306
    [No Abstract]   [Full Text] [Related]  

  • 14. Maintenance treatment of schizophrenia with long-acting fluphenazine.
    Niturad A; Ciurezu T; Cucu I
    Act Nerv Super (Praha); 1974 Aug; 16(3):167. PubMed ID: 4154028
    [No Abstract]   [Full Text] [Related]  

  • 15. Increase in gustatory acuity and hyperarousal in schizophrenia.
    Fischer R; Ristine LP; Wisecup P
    Biol Psychiatry; 1969 Jul; 1(3):209-18. PubMed ID: 4390893
    [No Abstract]   [Full Text] [Related]  

  • 16. Research design for analyzing drug-environment-behavior interactions.
    Liberman RP; Davis J; Moon W; Moore J
    J Nerv Ment Dis; 1973 Jun; 156(6):432-9. PubMed ID: 4711622
    [No Abstract]   [Full Text] [Related]  

  • 17. The hospitalization proneness scale as a predictor of response to phenothiazine treatment. II. Delay of psychiatric hospitalization.
    Rosen B; Engelhart DM; Freedman N; Margolis R; Klein DF
    J Nerv Ment Dis; 1971 Jun; 152(6):405-11. PubMed ID: 4935067
    [No Abstract]   [Full Text] [Related]  

  • 18. A double-blind comparison of the therapeutic efficacy of mesoridazine versus chlorpromazine.
    Freeman H; Oktem MR; Oktem N
    Curr Ther Res Clin Exp; 1969 May; 11(5):263-70. PubMed ID: 4977397
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of disorders of character and schizophrenia by pericyazine (Neulactil).
    Rasch PJ
    Acta Psychiatr Scand Suppl; 1966; 191():200-15. PubMed ID: 5336387
    [No Abstract]   [Full Text] [Related]  

  • 20. Prediction of response to phenothiazines in schizophrenia. A crossvalidation study.
    Goldberg SC; Frosch WA; Drossman AK; Schooler NR; Johnson GF
    Arch Gen Psychiatry; 1972 Apr; 26(4):367-73. PubMed ID: 4552130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.